Rankings
▼
Calendar
EVMN Q1 2025 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena
EVMN
Evommune, Inc.
$319M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-57.1% YoY
Gross Profit
$3M
87.4% margin
Operating Income
-$15M
-501.1% margin
Net Income
-$15M
-485.2% margin
EPS (Diluted)
$-0.48
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$24M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$56M
Total Liabilities
$214M
Stockholders' Equity
-$158M
Cash & Equivalents
$6M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$7M
-57.1%
Gross Profit
$3M
$7M
-61.0%
Operating Income
-$15M
-$4M
-300.4%
Net Income
-$15M
-$3M
-422.9%
← Q4 2024
All Quarters
Q2 2025 →